AVENIO ctDNA Surveillance Kits

Overview

The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy assay that’s specially designed and optimized to enable researchers to serial or longitudinal monitor tumor burden in Lung and Colorectal cancer over time. The Surveillance panel contains 197 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.¹

Features and Benefits of AVENIO ctDNA Surveillance Kits

• Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
• Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques^2,3
• Includes reagents, bioinformatics and software
• Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
  

Product Highlights

Detection of mutants with exceptional sensitivity and specificity^2,3

• >99% specificity for all classes of mutations
• >99% positive predictive value (PPV) for  all classes of mutations

• 17 assay targets in a single panel
• 180 additional genes with frequently mutated regions
• 471 frequently mutated regions associated with the presence of disease across 197 genes

The AVENIO ctDNA Targeted Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 77-gene AVENIO ctDNA Expanded Kit for profiling emerging and guideline-driven biomarkers.